摘要目的 评价上转发光免疫层析法定量检测乙型肝炎病毒外膜大蛋白(HBV-LP)在乙型肝炎患者中的应用价值.方法 利用一种新的基于上转发光法的免疫层析检测技术(UPT)检测500份乙肝病毒感染患者血清样品HBV-LP含量,并采用实时荧光定量PCR法检测HBV DNA;化学发光法检测乙肝五项指标.结果 500例乙肝病毒感染患者HBV-LP与HBV DNA阳性率分别为58.0％和42.2％,两者间差异有统计学意义(P＜0.01),其中215份HBeAg阴性患者血清中,HBVDNA与HBV-LP的阳性率分别为29.3％和37.2％,两者差异无统计学意义(P＞0.05);HBeAg阳性检出率为57.0％,与HBV DNA阳性检出率差异有统计学意义(P＜0.01).结论 上转发光免疫层析法检测乙肝病毒外膜大蛋白对HBeAg阴性和HBV DNA低拷贝患者体内病毒复制及预后评价有重要价值,联合检测HBV DNA、HBV-LP和HBeAg有利于乙肝病毒复制水平的判断和抗病毒治疗终点的确定.

abstractsObjective To evaluate the application value of the up-converting Phoshor technology immunochromatography for HBV large envelope protein (HBV-LP) quantitative determination strip in hepatitis B patients.Methods Serum HBV-LP was detected by a new UPT-based immunochromatograhpic technology,and HBV DNA was quantitively detected by real time fluorescent quantitation polymerase chain reaction (RT-PCR),HBV five serum markers were detected by chemiluminescence method.Results In 500 cases of patients with hepatitis B,HBV-LP and HBV DNA positive rates were 58.0％ and 42.2％ respectively,there was significant difference between the positive rate of HBV DNA and that of HBeAg(P ＜ 0.01); In 215 cases of HBeAg negative specimens,the positive rates of HBV DNA and HBV-LP were 29.3％ and 37.2％ respectively,the difference was statistically significant (P ＞ 0.05); and HBeAg positive rate was 57.0％,there was significant difference between the positive rate of HBV DNA and that of HBeAg (P ＜ 0.01).Conclusion HBV-LP detected by UPT method can be used for the evaluation of viral replication and prognosis of patients with HBeAg negative and HBV DNA low copies patients.Combing detection of HBV DNA,HBV-LP and HBeAg is conducive to the judgment of HBV replication level and determination of antiviral treatment end point.